Startvac

Country: ইউরোপীয় ইউনিয়ন

ভাষা: ইংরেজি

সূত্র: EMA (European Medicines Agency)

সক্রিয় উপাদান:

Escherichia coli J5 inactivated, Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime-associated antigenic complex

থেকে পাওয়া:

Laboratorios Hipra S.A.

এটিসি কোড:

QI02AB

INN (International Name):

adjuvanted inactivated vaccine for cattle against Staphylococcus aureus, coliforms and coagulase-negative staphylococci

Therapeutic group:

Cattle (cows and heifers)

Therapeutic area:

Immunologicals for bovidae

থেরাপিউটিক ইঙ্গিত:

For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulase-negative staphylococci.The full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days post-parturition).

পণ্য সারাংশ:

Revision: 3

অনুমোদন অবস্থা:

Authorised

অনুমোদন তারিখ:

2009-02-11

তথ্য লিফলেট

15
B. PACKAGE LEAFLET
16
PACKAGE LEAFLET FOR:
STARTVAC EMULSION FOR INJECTION FOR CATTLE
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Laboratorios Hipra S.A.
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
STARTVAC emulsion for injection for cattle
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
_ _
One dose (2 ml) contains:
_Escherichia coli _
(J5) inactivated
..........................................................................
> 50 RED
60
*
_Staphylococcus aureus_
(CP8) strain SP 140 inactivated, expressing slime associated antigenic
complex
(SAAC)........................................................................
........................................ > 50 RED
80
**
* RED
60
: Rabbit effective dose in 60% of the animals (serology).
** RED
80
: Rabbit effective dose in 80% of the animals (serology).
Liquid paraffin: 18.2 mg
Benzyl alcohol: 21 mg.
STARTVAC is an ivory-coloured homogeneous emulsion for injection.
4.
INDICATION(S)
For herd immunisation of healthy cows and heifers, in dairy cattle
herds with recurring mastitis
problems, to reduce the incidence of sub-clinical mastitis and the
incidence and the severity of the
clinical signs of clinical mastitis caused by
_Staphylococcus aureus_
, coliforms and coagulase-negative
staphylococci.
The full immunisation scheme induces immunity from approximately day
13 after the first injection
until approximately day 78 after the third injection.
5.
CONTRAINDICATIONS
None.
17
6.
ADVERSE REACTIONS
Very rare adverse reactions:
- Slight to moderate transient local reactions may occur after the
administration of one dose of vaccine
based on post-authorisation pharmacovigilance reporting. They would
mainly be: swelling (up to 5
cm
2
on average), which disappears within 1 or 2 weeks at most. In some
cases, there may also be pa

পণ্য বৈশিষ্ট্য

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
STARTVAC emulsion for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose (2 ml) contains:
ACTIVE SUBSTANCES:
_Escherichia coli _
J5 inactivated
.............................................................................
> 50 RED
60
*
_Staphylococcus aureus_
(CP8) strain SP 140 inactivated, expressing slime associated
antigenic complex (SAAC) .............
…………………………………………… > 50 RED
80
**
* RED
60
: Rabbit effective dose in 60% of the animals (serology).
** RED
80
: Rabbit effective dose in 80% of the animals (serology).
ADJUVANT:
Liquid
paraffin..............................................................................
18.2 mg
EXCIPIENT:
Benzyl
alcohol……………..........................................................
21 mg.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Emulsion for injection.
Ivory-coloured homogeneous emulsion.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle (cows and heifers).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For herd immunisation of healthy cows and heifers, in dairy cattle
herds with recurring mastitis
problems, to reduce the incidence of sub-clinical mastitis and the
incidence and the severity of the
clinical signs of clinical mastitis caused by
_Staphylococcus aureus_
, coliforms and coagulase-negative
staphylococci.
The full immunisation scheme induces immunity from approximately day
13 after the first injection
until approximately day 78 after the third injection.
4.3
CONTRAINDICATIONS
None.
3
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The whole herd should be immunised.
Immunisation has to be considered as one component in a complex
mastitis control program that
addresses all important udder health factors (e.g. milking technique,
dry-off and breeding
management, hygiene, nutrition, housing, bedding, cow comfort, air and
water quality, health
monitoring) and other management pra